Clinical trials: Cemiplimab
Non-Small Cell Lung Cancer
A Study of Cemiplimab Plus Chemotherapy Versus Cemiplimab Plus Chemotherapy Plus Other Cancer Treatments for Adult Patients With Operable Non-Small Cell Lung Cancer (NSCLC)
This study will enroll adult participants with early-stage (stage II-IIIB) non-small cell lung cancer for whom surgery is planned.
- Trial name
- NCT06465329
- Testing
- Cemiplimab, Platinum-based chemotherapy, REGN7075
- Where
- 47 sites in United States, Brazil and 4 more
- Volunteers
- 120 people
- Sponsor
- Regeneron Pharmaceuticals
Breast Cancer, Melanoma
Immunological Variables Associated to ICI Toxicity in Cancer Patients
This is a monocentric, prospective, pilot study that will enrol 435 subjects with solid tumours that are treated with immune checkpoint inhibitor(s) (ICI) alone or in combination with chemotherapy or targeted therapy.
- Conditions
- Breast Cancer, Melanoma, Non Small Cell Lung Cancer, Non-melanoma Skin Cancer
- Trial name
- NCT05429866
- Testing
- Checkpoint Blockade, Immune
- Where
- Belgium
- Volunteers
- 441 people
- Sponsor
- Jules Bordet Institute
Pleural Mesotheliomas
Trial Assessing Fianlimab Plus Cemiplimab Plus Chemotherapy or Cemiplimab Plus Chemotherapy in Patients With Pleural Mesothelioma
This is a multicentre, phase IIR, double non-comparative arm trial, with an initial safety run for the anti-LAG3 arm. Approximately 40 sites will participate in the study and will enroll 126 patients with treatment-naive…
- Trial name
- LAG-MAPS (NCT07234058)
- Testing
- Cemiplimab, Fianlimab, Pemetrexed (Alimta)
- Where
- 37 sites in France
- Volunteers
- 126 people
- Sponsor
- Intergroupe Francophone de Cancerologie Thoracique
NSCLC (Non-small Cell Lung Cancer), Hyperprogression
Hyperprogression in PD-L1 ≥ 50% NSCLC: a Biomarker Guided Phase 2 Trial
In metastatic NSCLC patients with PD-L1 expression ≥50%, a circulating immature (CD10-) LDNs level of ≥30.5% confers a high risk of hyperprogression (HPD) with first line single-agent immune-checkpoint inhibitors (SA-ICI).
- Trial name
- HYPERBOLIC (NCT07274384)
- Testing
- chemotherapy plus cemiplimab, Cemiplimab
- Volunteers
- 74 people
- Sponsor
- Università Vita-Salute San Raffaele
Locally Recurrent Oral Cavity Squamous Cell Carcinoma
Cemiplimab and Cetuximab Prior Salvage Surgery in Patients With Recurrent Oral Cavity and HPV-negative Oropharyngeal Squamous Cell Carcinoma
To learn if giving cemiplimab and cetuximab before salvage surgery can help to control recurrent oral cavity squamous cell carcinoma.
- Trial name
- NCT06448026
- Testing
- Cemiplimab, Cetuximab
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- M.D. Anderson Cancer Center
Recurrent Glioblastoma, IDH-Wildtype, Recurrent Gliosarcoma
Testing the Combination of Anti-cancer Drugs Actimab-A and Cemiplimab (REGN2810) to Improve Outcomes for Patients With Recurrent Glioblastoma
This phase I trial studies the side effects and best dose of Actimab-A when given together with cemiplimab (REGN2810) in treating patients with glioblastomas that have come back after a period of improvement (recurrent).
- Conditions
- Recurrent Glioblastoma, IDH-Wildtype, Recurrent Gliosarcoma, Recurrent WHO Grade 4 Glioma
- Trial name
- NCT07422363
- Testing
- Actinium Ac 225 Lintuzumab, Biospecimen Collection, Cemiplimab
- Volunteers
- 30 people
- Sponsor
- National Cancer Institute (NCI)
Melanoma
An Exploratory Tumor Biopsy-driven Study to Understand the Relationship Between Biomarkers and Clinical Response in Melanoma Patients Receiving REGN2810 (Anti-PD-1)
This study is being conducted to compare the relationship of patient response to treatment to changes in tumor environment.
- Trial name
- NCT03002376
- Testing
- REGN2810
- Where
- 8 sites in Netherlands, Serbia and 2 more
- Volunteers
- 47 people
- Sponsor
- Regeneron Pharmaceuticals
Advanced Melanoma
A Study of Fianlimab, Cemiplimab, and Ipilimumab in People With Melanoma
The purpose of this study is to test whether the combination of fianlimab, cemiplimab, and ipilimumab is a safe and effective treatment that causes few or mild side effects for locally advanced or metastatic, unresectable…
- Trial name
- NCT06594991
- Testing
- Fianlimab, Cemiplimab, Ipilimumab
- Where
- 12 sites in United States
- Volunteers
- 88 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Pancreatic Ductal Adenocarcinoma (mPDAC)
Cemiplimab Plus Gemcitabine in Patients With Metastatic Pancreatic Adenocarcinoma
This is a Phase 2 trial evaluating the combination of cemiplimab with the standard of care chemotherapy agent gemcitabine for the treatment of patients with metastatic pancreatic ductal adenocarcinoma with SWItch/Sucrose…
- Trial name
- SWITCH (NCT06790602)
- Testing
- Cemiplimab Plus Gemcitabine
- Where
- United States
- Volunteers
- 43 people
- Sponsor
- University of California, San Diego
Advanced Malignancies
Companion Study for Patients Who Completed Participation in a REGN2810 (Anti-PD-1) Clinical Study
This study has been designed to collect long-term follow-up information for patients who received REGN2810 in other clinical studies and to allow re-treatment for eligible patients.
- Trial name
- NCT02520245
- Testing
- REGN2810
- Where
- 9 sites in United States
- Sponsor
- Regeneron Pharmaceuticals
Triple Negative Breast Cancer, Clear Cell Renal Cell Carcinoma
Study of BDC-3042 as Single Agent and in Combination With Cemiplimab in Patients With Advanced Malignancies
A first-in-human study using BDC-3042 as a single agent and in combination with cemiplimab in patients with advanced malignancies
- Conditions
- Triple Negative Breast Cancer, Clear Cell Renal Cell Carcinoma, Ovarian Cancer, Head and Neck Cancer
- Trial name
- NCT06052852
- Testing
- BDC-3042, Cemiplimab
- Where
- 6 sites in United States
- Volunteers
- 17 people
- Sponsor
- Bolt Biotherapeutics, Inc.
Anaplastic Thyroid Cancer, Thyroid Cancer
XL092 and Cemiplimab in BRAF WT Thyroid Cancer
This multicenter study examines the safety and feasibility of the combination of neoadjuvant XL092 and cemiplimab prior to surgical resection in participants with wild-type (WT) anaplastic thyroid cancer (ATC) that has a BRAF…
- Conditions
- Anaplastic Thyroid Cancer, Thyroid Cancer, BRAF Mutation-Related Tumors
- Trial name
- NEO-COMBATXL (NCT06902376)
- Testing
- Cemiplimab, XL092
- Where
- 2 sites in United States
- Volunteers
- 12 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Metastatic Skin Squamous Cell Carcinoma, Recurrent Skin Squamous Cell Carcinoma
Cemiplimab Before and After Surgery for the Treatment of High Risk Cutaneous Squamous Cell Cancer
This phase I trial studies how well cemiplimab before and after surgery works in treating patients with high risk cutaneous squamous cell cancer.
- Trial name
- NCT04428671
- Testing
- Cemiplimab, Radiation Therapy, Therapeutic Conventional Surgery
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Emory University
Melanoma, Head and Neck Cancer
In Situ, Autologous Therapeutic Vaccination Against Solid Cancers With Intratumoral Hiltonol®
The purpose of this study is to evaluate the safety of sequential intratumoral (IT) plus intramuscular (IM) Polyinosinic-polycytidylic acid stabilized with polylysine and carboxymethylcellulose (poly-ICLC, Hiltonol®) for…
- Conditions
- Melanoma, Head and Neck Cancer, Sarcoma, Non-Melanoma Skin Cancers
- Trial name
- Poly-ICLC (NCT02423863)
- Testing
- Hiltonol
- Where
- 5 sites in United States
- Volunteers
- 26 people
- Sponsor
- Oncovir, Inc.
Advanced Solid Tumors, NSCLC
Evaluating Length of Treatment With PD-1/PD-L1 Inhibitor in Advanced Solid Tumors
Based on the overwhelming positive response to this survey and the large number of patients being treated with PD-1/PD-L1 therapy in the UPMC system, the investigators are proposing a trial that will randomize patients who have…
- Conditions
- Advanced Solid Tumors, NSCLC, Bladder Cancer, HNSCC
- Trial name
- NCT04157985
- Testing
- Continue PD-1/PD-L1 Inhibitors treatment, Discontinue PD-1/PD-L1-1 inhibitor
- Where
- United States
- Volunteers
- 161 people
- Sponsor
- Dan Zandberg
Anaplastic Thyroid Cancer, Thyroid Cancer
Study of Cemiplimab Combined With Dabrafenib and Trametinib in People With Anaplastic Thyroid Cancer
This study is being done to see if adding the study drug, cemiplimab, to the standard therapy with dabrafenib and trametinib is an effective treatment against anaplastic thyroid cancer.
- Conditions
- Anaplastic Thyroid Cancer, Thyroid Cancer, BRAF Gene Mutation, BRAF Mutation-Related Tumors
- Trial name
- NCT04238624
- Testing
- Dabrafenib, Trametinib
- Where
- 7 sites in United States
- Volunteers
- 16 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Non-Small Cell Lung Cancer
Cemiplimab for Clinical Stage I, 2-3.9cm, Non-Small Cell Lung Cancer
The study will investigate the role of cemiplimab in combination with platinum doublet chemotherapy in stage I resectable non-small cell lung cancer (NSCLC).
- Trial name
- NCT07720167
- Testing
- Cemiplimab, Carboplatin + Pemetrexed/Paclitaxel, Cisplatin
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- Medical University of South Carolina
Cutaneous Squamous Cell Carcinoma (CSCC)
Next-gen Flow Cytometry to Find Immune Profiles, Treatment Response, and Toxicity Markers in Skin Cancer Patients Treated With Cemiplimab.
Cutaneous squamous cell carcinoma (CSCC) is the second most frequent cancer in humans, it exhibits a high tumor mutational burden and is more common in immunocompromised patients, which aimed to explore the impact of…
- Trial name
- NGF-GRACE (NCT07064330)
- Testing
- Cemiplimab
- Where
- Spain
- Volunteers
- 30 people
- Sponsor
- Instituto de Investigación Biomédica de Salamanca
Carcinoma, Non-Small-Cell Lung
THIO Sequenced With Cemiplimab in Advanced NSCLC
THIO is a first-in-class small molecule telomere targeting agent, in development for the treatment of non-small cell lung cancer (NSCLC) in combination with cemiplimab (LIBTAYO®).
- Trial name
- NCT05208944
- Testing
- 6-Thio-2'-Deoxyguanosine, Cemiplimab
- Where
- 40 sites in United States, Australia and 6 more
- Volunteers
- 227 people
- Sponsor
- Maia Biotechnology
Cancer/Squamous Cell Carcinoma of Skin
Comparative Efficacy of Cemiplimab to Historical Standard of Care in France
Primary Objective: -Assess the effectiveness of cemiplimab versus other available systemic therapies in patients up to 2018 or say historical system organ class (SOC) with metastatic or locally advanced cutaneous Squamous Cell…
- Trial name
- TOSCA (NCT05302297)
- Testing
- Cemiplimab
- Where
- France
- Volunteers
- 305 people
- Sponsor
- Sanofi